What is the recommended management for gastroparesis, including dietary modifications, prokinetic agents, and second‑line therapies?

Management of Gastroparesis

Begin with dietary modifications (small particle size, low-fat, low-residue diet) and optimize glycemic control in diabetics, then initiate metoclopramide (5 mg three times daily before meals) or erythromycin (40-150 mg before meals) as first-line prokinetic therapy, with treatment response assessed at 4-8 weeks. 1

Initial Management Steps

Before starting any pharmacologic therapy, address these critical factors:

• Optimize glycemic control in diabetic patients, as hyperglycemia directly impairs gastric emptying 1
• Eliminate medications that delay gastric emptying: opioids, GLP-1 receptor agonists, anticholinergics, and cannabis 1, 2
• Confirm diagnosis with 4-hour gastric emptying scintigraphy showing >10% retention 1
• Classify severity: mild (10-15% retention), moderate (16-35%), or severe (>35%) 3

Dietary Modifications (First-Line for All Patients)

Implement dietary changes before or concurrent with medications:

• Small particle diet: blend or chop food into small pieces 2
• Low-fat content: fat delays gastric emptying 1
• Low-residue: avoid high-fiber foods that are difficult to digest 1
• For severe cases, consider liquid diet or jejunal enteral feeding 2

Antiemetic Therapy (Symptomatic Relief)

Use antiemetics as needed for nausea and vomiting—these do not affect gastric emptying but provide symptom relief:

• 5-HT3 antagonists: ondansetron 4-8 mg twice or three times daily, or granisetron 1 mg twice daily 1, 3
• Histamine H1 antagonists: promethazine 1
• Dopamine D2 antagonists: prochlorperazine 5-10 mg four times daily 1, 3

First-Line Prokinetic Agents

Metoclopramide (Conditional Recommendation, Low Quality Evidence)

The AGA suggests using metoclopramide as first-line prokinetic therapy 1

Dosing protocol:

• Start with 5 mg orally three times daily before meals
• Titrate up to 10 mg three times daily based on response 1
• Intranasal formulation: 15 mg before meals and at bedtime 1

Critical safety considerations:

• FDA black box warning for tardive dyskinesia risk 1
• Discuss adverse effects before initiating therapy 1
• Higher risk in elderly patients and those on psychotropic agents, though absolute risk remains low 1
• Consider drug holidays (1-4 weeks off every 8-12 weeks) to improve tolerability 1
• Assess efficacy and adverse effects at 4-8 weeks to determine continuation 1

Erythromycin (Conditional Recommendation, Low Quality Evidence)

The AGA suggests using erythromycin as first-line prokinetic therapy 1

Dosing protocol:

• Use low doses: 40-150 mg orally 30 minutes before meals 1
• Use erythromycin ethylsuccinate oral suspension to allow smaller doses, as tablets only come in high doses (250-500 mg) 1

Critical considerations:

• Works via motilin receptor agonism, not antibiotic properties 1
• Tachyphylaxis develops with continuous use—maintain efficacy with drug holidays (e.g., 3 weeks on, 1 week off) 1
• Safety concerns: antibiotic resistance with long-term use, drug interactions (CYP3A inhibitor), QT prolongation 1
• Azithromycin used as substitute in practice with similar considerations 1

Second-Line and Symptom-Targeted Therapies

When first-line agents fail or are not tolerated, use shared decision-making to select from these options based on predominant symptoms:

For Predominant Nausea/Vomiting with Metoclopramide Intolerance:

• Domperidone (not FDA-approved in US; requires expanded access) 1
  • Especially useful for patients with neurologic adverse effects from metoclopramide or those with Parkinson's disease 1
  • AGA suggests against as first-line but reasonable in shared decision-making 1

For Predominant Nausea/Vomiting with Constipation:

• Prucalopride (5-HT4 agonist) 1

For Predominant Abdominal Pain:

• Nortriptyline 25-100 mg daily 1, 3
  • Particularly useful with overlapping IBS, functional dyspepsia, or significant pain 1
  • Start low dose, increase slowly 1
  • Explain to patients this is used as peripheral neuromodulator, not for depression 1
  • AGA suggests against as first-line but reasonable for pain-predominant symptoms 1

For Predominant Early Satiety and Fullness:

• Buspirone 1
  • AGA suggests against as first-line but may be reasonable in shared decision-making 1

Other Second-Line Options:

• Aprepitant (NK-1 antagonist): 80 mg daily 3
• Cannabidiol: AGA suggests against due to lack of available pharmaceutical-grade formulations and concern for cannabis hyperemesis syndrome with THC-containing products 1

Refractory Gastroparesis Management

For patients failing medical therapy with severe, refractory symptoms:

Gastric Electrical Stimulation (GES)

• Consider for refractory/intractable nausea and vomiting after failed standard therapy 3
• Contraindication: patients on opioids 3
• Approved under Humanitarian Device Exemption 4
• Long-term data shows ≥50% reduction in symptoms in 58% of diabetic, 53% of post-surgical, and 48% of idiopathic gastroparesis 5
• Device infection requiring removal occurs in ~7% 5

Gastric Per-Oral Endoscopic Myotomy (G-POEM)

• Consider for select refractory patients with severe delay in gastric emptying 3
• Requires thoughtful team approach with motility specialists and advanced endoscopists at center of excellence 3
• AGA issues conditional recommendation against routine initial use, reserving for refractory cases 1

Enteral Nutrition

• Jejunal feeding tube for severe gastroparesis unable to maintain nutrition orally 2, 6

Treatment Assessment Algorithm

At 4-8 weeks:

• Assess symptom improvement using gastroparesis symptom scales
• Evaluate for adverse effects (especially movement disorders with metoclopramide)
• Decision point: Continue, adjust dose, switch agents, or add second-line therapy 1

Common Pitfalls to Avoid

• Do not use opioids for gastroparesis-associated pain—they worsen gastric emptying 3
• Do not use high-dose erythromycin (250-500 mg)—increases adverse effects and tachyphylaxis 1
• Do not continue metoclopramide indefinitely without monitoring for tardive dyskinesia 1
• Do not overlook glycemic control in diabetic patients—hyperglycemia directly impairs motility 1
• Do not use botulinum toxin injection routinely—randomized trials showed no efficacy 4

Nuances in Evidence Quality

The 2025 AGA guideline 1 represents the most current evidence but acknowledges low to very low quality evidence for most interventions. All prokinetic recommendations are conditional, reflecting limited robust trial data. The guideline emphasizes shared decision-making given the balance between modest symptom improvement and potential adverse effects. Notably, metoclopramide remains the only FDA-approved medication for gastroparesis despite its black box warning 7.

The 2022 AGA clinical practice update 3 complements the 2025 guideline by providing practical advice for refractory cases, emphasizing symptom-targeted therapy rather than treating delayed emptying alone, as symptoms often do not correlate with gastric emptying times.